BRIEF-ALX Oncology Q4 Basic EPS USD -0.42
Summary
ALX Oncology Holdings Inc. reported a Q4 Basic EPS of -$0.42, alongside operating expenses of $23.021 million and a net loss of $22.848 million for the quarter. This financial update provides a direct look into the company's recent performance. For a clinical-stage biotechnology company, these results are a key indicator of its cash burn and operational efficiency. Traders will be assessing these figures against expectations and looking for any forward-looking statements regarding clinical trial progress or future financing needs, which are critical for the company's valuation.
At the time of this announcement, ALXO was trading at $2.48 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $308.3M. The 52-week trading range was $0.40 to $2.66. This news item was assessed with negative market sentiment and an importance score of 7 out of 10. Source: Reuters.